Medtronic plc s in-depth stock price analysis indicates that the stock price has dropped -5.91% in the past 12 Weeks but analyzing the 6 month chart of the stock, the price of the stock has managed to drop negative and it has dropped down to -12.07% . Looking at the past 52 week period, the stock price is up at 3.75% . Relative price strength is a important factor used by wealth management firms while investing in stocks since the indicator compares the stock performance with the overall market. The relative price strength of Medtronic plc has a negative value of -5.03 compared to overall market performance. Medtronic plc (NYSE:MDT) has tumbled 0.25% during the past week, however, the bigger picture is still very bullish; the stocks have advanced and posted positive gains of 1.41% in the last four weeks. The stocks are negative as compared to the S&P 500 for the past week with a loss of 1.05%. Medtronic plc (NYSE:MDT) has underperformed the index by 0.4% in the last 4 weeks. Investors should watch out for further signals and trade with caution.
Medtronic plc (NYSE:MDT) : On Friday heightened volatility was witnessed in Medtronic plc (NYSE:MDT) which led to swings in the share price. The stock opened for trading at $75.85 and hit $76.26 on the upside , eventually ending the session at $76.15, with a gain of 0.58% or 0.44 points. The heightened volatility saw the trading volume jump to 3,427,117 shares. The 52-week high of the share price is $89.27 and the company has a market cap of $104,558 million. The 52-week low of the share price is at $69.35 .
Medtronic PLC Last issued its quarterly earnings results on Nov 22, 2016. The company reported $1.12 EPS for the quarter, beating the analyst consensus estimate by $ 0.01. Analyst had a consensus of $1.11. The company had revenue of $7345.00 million for the quarter, compared to analysts expectations of $7459.64 million. The companys revenue was up 4.1% compared to the same quarter last year. During the same quarter in the previous year, the company posted $1.03 EPS.
Several Stock Research Financial Advisors from Investment Banking firms have advised their client and investors on the stock.Medtronic PLC was Downgraded by BofA/Merrill to Neutral on Jan 3, 2017. Medtronic PLC was Downgraded by JP Morgan to Neutral on Jan 3, 2017. Medtronic PLC was Downgraded by Morgan Stanley on Jan 3, 2017 to Equal-Weight, Price Target of the shares are set at $77.Medtronic PLC was Reiterated by Needham on Nov 23, 2016 to Buy, Lowers Price Target to $ 84 from a previous price target of $95 .Medtronic PLC was Reiterated by Stifel on Nov 23, 2016 to Hold, Lowers Price Target to $ 81 from a previous price target of $91 .
Company has reported several Insider transactions to the SEC, on Dec 14, 2016, Robert C Pozen (director) purchased 13,660 shares at 73.21 per share price.On Nov 23, 2016, James T Lenehan (director) purchased 2,000 shares at 73.27 per share price.On Sep 28, 2016, Richard Kuntz (SrVP & Chief Scien, Clin, Reg) sold 42,340 shares at 86.68 per share price.
Medtronic is the worlds leading medical technology company, pioneering device-based therapies that restore health, extend life and alleviate pain. Primary products include those for bradycardia pacing, tachyarrhythmia management, atrial fibrillation management, among others. Medtronic operates its business in one reportable segment, that of manufacturing and selling device-based medical therapies. The company does business in more than 120 countries. The companys product lines include cardiac rhythm management, neurological and spinal, vascular and cardiac surgery.